English | Español
Patient Daily | Feb 6, 2026

Pfizer releases early Metsera obesity drug data; FDA decisions expected on key therapies
Patient Daily | Feb 6, 2026

Amgen highlights extended dosing potential for obesity drug MariTide
Patient Daily | Feb 6, 2026

Amgen declines FDA request to withdraw rare disease drug Tavneos
Patient Daily | Feb 6, 2026

Novartis maintains acquisition focus while reporting strong financial results
Patient Daily | Feb 6, 2026

GSK focuses on complications from obesity rather than GLP-1 drugs
Patient Daily | Feb 6, 2026

Eli Lilly sees opportunity as Novo Nordisk's oral Wegovy expands obesity drug market
Patient Daily | Feb 6, 2026

Congressman questions transparency of FDA's priority voucher program
Patient Daily | Feb 6, 2026

Eli Lilly expands tirzepatide trials into immunology with combination therapies

Trending
+ Pharmaceuticals
Patient Daily | Apr 5, 2026

Amplifon announces $2 billion acquisition of GN Hearing in strategic shift
Patient Daily | Apr 7, 2026

ProPublica examines impact of RFK Jr.'s vaccine policies on childhood disease risks
+ Pharmaceuticals
Patient Daily | Apr 1, 2026

Biopharma mergers and acquisitions reach $46.8 billion in first quarter of 2026
+ Regulatory
Patient Daily | Apr 8, 2026

Columbia University Professor Masia on 340B: '340B has become a drug mark-up program. Hospitals buy drugs at low cost and sell them high'